33 related articles for article (PubMed ID: 11510694)
1. Tumor slice culture system to assess drug response of primary breast cancer.
Naipal KA; Verkaik NS; Sánchez H; van Deurzen CH; den Bakker MA; Hoeijmakers JH; Kanaar R; Vreeswijk MP; Jager A; van Gent DC
BMC Cancer; 2016 Feb; 16():78. PubMed ID: 26860465
[TBL] [Abstract][Full Text] [Related]
2. Preventive effect of free radical scavenger edaravone lotion on cyclophosphamide chemotherapy-induced alopecia.
Tsuji T; Yoneda K; Igawa Y; Minamino E; Otani N; Yoshida Y; Kohno T
Cancer Chemother Pharmacol; 2024 Apr; ():. PubMed ID: 38642149
[TBL] [Abstract][Full Text] [Related]
3. Cancer Stem Cell Assay for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer.
Howard CM; Bush S; Zgheib NB; Lirette ST; Cortese A; Mollo A; Valluri J; Claudio PP
HSOA J Stem Cells Res Dev Ther; 2021; 7(3):. PubMed ID: 34796266
[TBL] [Abstract][Full Text] [Related]
4.
Tognon CE; Sears RC; Mills GB; Gray JW; Tyner JW
Annu Rev Cancer Biol; 2021 Mar; 5():39-57. PubMed ID: 34222745
[TBL] [Abstract][Full Text] [Related]
5. Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients.
Ulukaya E; Karakas D; Dimas K
Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34205407
[TBL] [Abstract][Full Text] [Related]
6. Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test).
Kischkel FC; Meyer C; Eich J; Nassir M; Mentze M; Braicu I; Kopp-Schneider A; Sehouli J
J Ovarian Res; 2017 Oct; 10(1):72. PubMed ID: 29078793
[TBL] [Abstract][Full Text] [Related]
7. New
Kischkel FC; Eich J; Meyer CI; Weidemüller P; Krapfl J; Yassin-Kelepir R; Job L; Fraefel M; Braicu I; Kopp-Schneider A; Sehouli J; De Wilde RL
PeerJ; 2017; 5():e3030. PubMed ID: 28265509
[TBL] [Abstract][Full Text] [Related]
8. Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.
Morgan MM; Johnson BP; Livingston MK; Schuler LA; Alarid ET; Sung KE; Beebe DJ
Pharmacol Ther; 2016 Sep; 165():79-92. PubMed ID: 27218886
[TBL] [Abstract][Full Text] [Related]
9. Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer.
Bussmann L; Busch CJ; Lörincz BB; Rieckmann T; Block A; Knecht R
Eur Arch Otorhinolaryngol; 2016 Dec; 273(12):4073-4080. PubMed ID: 26755047
[TBL] [Abstract][Full Text] [Related]
10. A novel 96well-formatted micro-gap plate enabling drug response profiling on primary tumour samples.
Ma WY; Hsiung LC; Wang CH; Chiang CL; Lin CH; Huang CS; Wo AM
Sci Rep; 2015 Apr; 5():9656. PubMed ID: 25866290
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-mesenchymal transition contributes to docetaxel resistance in human non-small cell lung cancer.
Shen W; Pang H; Liu J; Zhou J; Zhang F; Liu L; Ma N; Zhang N; Zhang H; Liu L
Oncol Res; 2014; 22(1):47-55. PubMed ID: 25700358
[TBL] [Abstract][Full Text] [Related]
12. Recent applications of chemosensitivity tests for colorectal cancer treatment.
Yoon YS; Kim JC
World J Gastroenterol; 2014 Nov; 20(44):16398-408. PubMed ID: 25469008
[TBL] [Abstract][Full Text] [Related]
13. In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study.
Kim HS; Kim TJ; Chung HH; Kim JW; Kim BG; Park NH; Song YS; Bae DS; Kang SB
J Cancer Res Clin Oncol; 2009 Nov; 135(11):1513-20. PubMed ID: 19449027
[TBL] [Abstract][Full Text] [Related]
14. Prediction of drug response in breast cancer using integrative experimental/computational modeling.
Frieboes HB; Edgerton ME; Fruehauf JP; Rose FR; Worrall LK; Gatenby RA; Ferrari M; Cristini V
Cancer Res; 2009 May; 69(10):4484-92. PubMed ID: 19366802
[TBL] [Abstract][Full Text] [Related]
15. A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma.
Parker RJ; Fruehauf JP; Mehta R; Filka E; Cloughesy T
J Neurooncol; 2004 Feb; 66(3):365-75. PubMed ID: 15015670
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay.
Mehta RS; Bornstein R; Yu IR; Parker RJ; McLaren CE; Nguyen KP; Li KT; Fruehauf JP
Breast Cancer Res Treat; 2001 Apr; 66(3):225-37. PubMed ID: 11510694
[TBL] [Abstract][Full Text] [Related]
17. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
18. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
